NewAmsterdam Pharma's Upcoming Presentation
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is gearing up for an exciting participation at the renowned Stifel 2025 Virtual Cardiometabolic Forum. The company, well-regarded for its late-stage development of oral non-statin medicines for cardiovascular disease (CVD), is set to feature prominently in discussions aimed at improving patient care and addressing significant medical needs.
Engagement of Key Executives
During the forum, scheduled for a future date, the spotlight will be on John Kastelein, the Chief Scientific Officer, and Matthew Philippe, the Executive Vice President, who will engage the audience in a virtual fireside chat. Their insights are expected to provide valuable perspectives on the innovative work being done at NewAmsterdam, specifically in the realm of treating patients with elevated low-density lipoprotein cholesterol (LDL-C).
Live Webcast Experience
For those interested in learning more about NewAmsterdam's advancements, the company will make a live webcast available through their investor relations section. Following the chat, an archived replay can also be accessed on their official website, ensuring broader reach and engagement with stakeholders and the public alike.
The Mission of NewAmsterdam Pharma
At the heart of NewAmsterdam's mission lies a commitment to enhance patient lives, particularly in populations battling metabolic diseases where existing therapies have fallen short. The company aims to provide a safe, well-tolerated, and practical LDL-lowering therapy, addressing a significant gap in treatment options currently available.
Clinical Trials and Innovations
In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose CETP inhibitor aimed at reducing LDL-C levels among those at risk of CVD. This treatment is being studied both individually and as a fixed-dose combination with ezetimibe, offering promising results for patients who are not achieving desired outcomes with existing therapies.
Company Contact Information
For inquiries, Matthew Philippe is available at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com. Interested parties can also reach out to the media contact, Christian Edgington at Real Chemistry, at 1-513-310-6410 or at cedgington@realchemistry.com.
Frequently Asked Questions
What is the focus of NewAmsterdam Pharma?
NewAmsterdam Pharma focuses on developing innovative oral medications for lowering cholesterol in patients at risk of cardiovascular disease.
Who will be speaking at the Stifel 2025 Virtual Cardiometabolic Forum?
John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, will represent NewAmsterdam Pharma during the event.
How can I watch the live presentation?
The presentation will be available via a live webcast through the investor relations section of NewAmsterdam's official website.
What is obicetrapib?
Obicetrapib is an experimental therapy being investigated by NewAmsterdam as a treatment option for lowering LDL cholesterol in patients with cardiovascular risks.
How can I contact NewAmsterdam Pharma?
You can contact Matthew Philippe at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.